Efficacy and safety of rivaroxaban in preventing venous thromboembolism in postoperative patients with gynecological malignancies: protocol for a randomised controlled open-label trial (G-alfalfa trial)
Introduction Compared with the guideline-recommended use of low-molecular weight heparin (LMWH) for 28 days to prevent venous thromboembolism (VTE) after cytoreductive surgery, oral rivaroxaban avoids the pain and inconvenience of daily injections and reduces medical expenses. The proposed randomise...
Saved in:
Main Authors: | Hong Zhou, Fei He, Ting Wei, Shuyi Wu, Jinhua Zhang, Huan Yi |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2024-12-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/14/12/e092164.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cost-Consequence Analysis of Apixaban Versus Rivaroxaban for Managing Patients with Venous Thromboembolism
in Saudi Arabia
by: Abdulaali R. Almutairi PhD, et al.
Published: (2025-02-01) -
Risk of recurrence and bleeding in patients with cancer‐associated venous thromboembolism treated with rivaroxaban: A nationwide cohort study
by: Mette Søgaard, et al.
Published: (2019-03-01) -
Effectiveness and Safety of Nonvitamin K Oral Anticoagulants Rivaroxaban and Apixaban in Patients with Venous Thromboembolism: A Meta-Analysis of Real-World Studies
by: Olivia Wu, et al.
Published: (2022-01-01) -
Risk assessment and prevention of cancer-associated venous thromboembolism in ambulatory patients with solid malignancies
by: Nikola Vladic, et al.
Published: (2025-01-01) -
Open-label randomised clinical trial investigating whether robot-assisted kidney transplantation can reduce surgical complications compared to open kidney transplantation (ORAKTx): study protocol for a randomised clinical trial
by: Milla Ortved, et al.
Published: (2025-01-01)